|
|
|
|||||||||||
|
|
|
|||||||
|
|||||||
|
|
Professional Resources>
|
| Web Resources The following organizations include medical, consumer, and patient advocacy groups. They offer a wealth of information for both you and your patients. The Web sites below are external to GlaxoSmithKline. GlaxoSmithKline does not possess editorial control over the content of the information provided in these Web sites and therefore does not warrant their accuracy or completeness. American Academy of Neurology (AAN) 1080 Montreal Avenue Saint Paul, MN 55116 800-879-1960 651-695-2791 (Fax) www.aan.com American Association of Neuroscience Nurses (AANN) 4700 W. Lake Avenue Glenview, IL 60025 888-557-2266 (US only) 877-734-8677 (Fax) www.aann.org American Epilepsy Society (AES) 342 North Main Street West Hartford, CT 06117 860-586-7505 860-586-7550 (Fax) www.aesnet.org American Therapeutic Recreation Association (ATRA) 1414 Prince Street, Suite 204 Alexandria, VA 22314 703-683-9420 703-683-9431 (Fax) www.atra-tr.org Child Neurology Society (CNS) 1000 West Country Road E, Suite 290 Saint Paul, MN 55126 651-486-9447 651-486-9436 (Fax) www.childneurologysociety.org Citizens United for Research in Epilepsy (CURE) 730 N. Franklin Street, Suite 404 Chicago, IL 60610 312-255-1801 312-255-1809 (Fax) www.CUREepilepsy.org Epilepsy Foundation This Web site also includes the Women and Epilepsy Initiative. 8301 Professional Place Landover, MD 20785 800-332-1000 www.epilepsyfoundation.org Family Caregiver Alliance (FCA) 180 Montgomery Street, Suite 1100 San Francisco, CA 94104 800-445-8106 415-434-3508 (Fax) www.caregiver.org Healthfinder® (Department of Health and Human Services Web site) PO Box 1133 Washington, DC 20013-1133 www.healthfinder.gov National Association of Epilepsy Centers (NAEC) 5775 Wayzata Boulevard, Suite 200 Minneapolis, MN 55416 888-525-6232 952-525-1560 (Fax) www.naecepilepsy.org National Council on Patient Information and Education (NCPIE) 4915 Saint Elmo Avenue, Suite 505 Bethesda, MD 20814-6082 301-656-8565 301-656-4464 (Fax) www.talkaboutrx.org National Family Caregivers Association (NFCA) 10400 Connecticut Avenue, Suite 500 Kensington, MD 20895-3944 800-896-3650 301-942-2302 (Fax) www.nfcacares.org National Institute of Neurological Disorders and Stroke (NINDS) PO Box 5801 Bethesda, MD 20824 800-352-9424 www.ninds.nih.gov National Organization for Rare Disorders (NORD) 55 Kenosia Avenue PO Box 1968 Danbury, CT 06813-1968 203-744-0100 800-999-6673 (voicemail only) 203-798-2291 (Fax) www.rarediseases.org Seizures & Epilepsy Education (SEE) 2122 Rock Hollar Road Stanley, NC 28164 704-263-7167 800-397-3605 www.theseeprogram.com Society for Neuroscience (SFN) 1121 14th Street NW, Suite 1010 Washington, DC 20005 202-962-4000 www.sfn.org Resources for Your Patients offers specialized information from GlaxoSmithKline that can be useful in the treatment and management of epilepsy. For the latest medical updates on epilepsy treatment, visit the Web sites for the American Epilepsy Society, the American Academy of Neurology, and the Child Neurology Society. |
|
|||||||
|
|
|||||||
|
| • | Safety and effectiveness of LAMICTAL have not been established 1) as initial monotherapy, 2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate, or 3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs |
| Important Safety Information | |
| • | Serious rashes requiring hospitalization and discontinuation of treatment have been reported in association with the use of LAMICTAL, some of which have included Stevens-Johnson syndrome |
| — Epilepsy clinical trials: The incidence of these rashes is approximately 0.8% (8/1000) in pediatric patients (age <16 years) receiving LAMICTAL as adjunctive therapy for epilepsy and 0.3% (3/1000) in adults on adjunctive therapy for epilepsy. In a prospectively followed cohort of 1983 pediatric patients with epilepsy taking adjunctive LAMICTAL, there was 1 rash-related death | |
| — Mood disorders: In clinical trials of bipolar and other mood disorders, the incidence of these rashes was 0.08% (0.8/1000) in adults receiving LAMICTAL as initial monotherapy and 0.13% (1.3/1000) in adult patients receiving LAMICTAL as adjunctive therapy | |
| • | In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate |
| • | Hypersensitivity reactions, some fatal or life-threatening, have occurred in association with the use of LAMICTAL. It is important to note that early manifestations of hypersensitivity (eg, fever, lymphadenopathy) may be present even though a rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately, and LAMICTAL should be discontinued if an alternative etiology cannot be established |
| • | Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (eg, fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately |
| • | To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations of LAMICTAL should not be exceeded |
| • | LAMICTAL should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug-related |
Complete Prescribing Information for LAMICTAL® (lamotrigine) Tablets |
|
This site is intended for US healthcare professionals only. © 1997-2008 GlaxoSmithKline. All Rights Reserved. |
|